A systematic review of genetic associations, autoantibody profiles, and research gaps of peptidyl arginine deiminases type 2 (PAD2) and PAD4 in rheumatoid arthritis
Autoimmunity Reviews · 2026-11 · 25 (11) · 104147
DOI: 10.1016/j.autrev.2026.104147 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Autoimmunity Reviews, 2026-11. Verfasst von Abang Ulrich Akwo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Biotechnology, Pan African University Institute for Basic Sciences, Technology and Innovation, Nairobi, Kenya; De…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Protein-Arginine Deiminase Type 4, Autoantibodies, Protein-Arginine Deiminase Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Peptidylarginine deiminases (PAD) 2 and 4 are pivotal enzymes in the pathophysiology of RA, owing to their involvement in protein citrullination, which produces autoantigens recognised by anti-citrullinated protein antibodies (ACPAs). Genetic variations in PADI2 and PADI4, along with autoantibodies targeting these enzymes, have been identified as significant contributors to the susceptibility and heterogeneity of RA. This systematic review with narrative synthesis consolidates existing evidence on the correlations between PADI2/PADI4 polymorphisms and the risk of RA, alongside the prevalence and clinical implications of anti-PAD2 and anti-PAD4 autoantibodies, with particular emphasis on identifying research deficiencies in underrepresented communities. A thorough literature review of PubMed, Web of Science, Scopus, Embase, and Google Scholar was performed until March 2024 for studies examining PADI2/PADI4 genetics or anti-PAD antibodies in patients with RA. No geographical or linguistic restrictions were applied. Forty-two genetic studies and 18 autoantibody studies were included. PADI4 polymorphisms exhibit notable relationships with RA in Asian populations (pooled odds ratio 1.23, 95% confidence interval 1.16-1.31); however, the results are equivocal among Europeans. A protective PADI2 variation (rs1005753) was discovered in Southeast Asians (OR = 0.87 (95% CI =0.77-0.99)). Anti-PAD4 antibodies (18-35% prevalence) were correlated with severe erosive disease, whereas anti-PAD2 antibodies (∼18.5% prevalence) were correlated with milder disease. No studies pertaining to genetics or autoantibody profiles in African populations were found. Substantial advancements have been made in understanding PAD2 and PAD4 in Asian and European populations. The lack of data from African populations constitutes a significant research gap that necessitates immediate focus to guarantee the equitable implementation of biomarkers and therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Biotechnology, Pan African University Institute for Basic Sciences, Technology and Innovation, Nairobi, Kenya; Department of Biochemistry, Faculty of Science, University of Bamenda, B…
- Department of Biochemistry, Faculty of Science, University of Bamenda, Bambili, Cameroon.
- Department of Zoology, Faculty of Science, University of Bamenda, Bambili, Cameroon.
Zitieren
APA
Akwo, A. U., Ketu, K. V., & Mahamat, O. (2026). A systematic review of genetic associations, autoantibody profiles, and research gaps of peptidyl arginine deiminases type 2 (PAD2) and PAD4 in rheumatoid arthritis. Autoimmunity Reviews, 25(11), 104147. https://doi.org/10.1016/j.autrev.2026.104147
Vancouver
Akwo AU, Ketu KV, Mahamat O. A systematic review of genetic associations, autoantibody profiles, and research gaps of peptidyl arginine deiminases type 2 (PAD2) and PAD4 in rheumatoid arthritis. Autoimmunity Reviews. 2026;25(11):104147. doi:10.1016/j.autrev.2026.104147
BibTeX
@article{Akwo2026,
author = {Akwo, Abang Ulrich and Ketu, Ketonze Valademy and Mahamat, Oumar},
title = {A systematic review of genetic associations, autoantibody profiles, and research gaps of peptidyl arginine deiminases type 2 (PAD2) and PAD4 in rheumatoid arthritis},
journal = {Autoimmunity Reviews},
year = {2026},
volume = {25},
number = {11},
pages = {104147},
doi = {10.1016/j.autrev.2026.104147}
}
EUVIMED